2020
conference-abstract
OpenAlex
Nausheen Hakim, Jeffrey Chi, Hasan Rehman, William H. Nealon et autres
4628 Background: ESPAC-4 study showed that GemCap conferred a survival benefit over gemcitabine monotherapy in resected PC patients. ESPAC-4 included patients with median age of 65 years (37-81) and ECOG performance status (PS) of 0 (43%), 1 (54%) and 2 (2%) who …
us
(code pays fourni par la source)
2020
conference-abstract
OpenAlex
Hasan Rehman, Jeffrey Chi, Nausheen Hakim, Jyothi Jose et autres
e16791 Background: There is a paucity of data to guide treatment for rPDAC after curative resection and gemcitabine-based adjuvant chemotherapy. Our aim was to investigate whether combination treatment upfront with all active agents is better than sequential administration of these drugs in …
us
(code pays fourni par la source)
2020
conference-abstract
OpenAlex
Jeffrey Chi, Nausheen Hakim, Hasan Rehman, Linda Moriarty et autres
e16138 Background: 5-FU and IRI are core components of chemotherapies for GI malignancies. Previous studies have shown that mutations in DPYP and TYMS predispose the pts to 5-FU toxicities. Mutations in UGT1A1 predispose pts to increased IRI toxicities. Retrospective data suggest that …
us
(code pays fourni par la source)
2020
conference-abstract
OpenAlex
Nausheen Hakim, Jeffrey Chi, Hasan Rehman, Shreya Goyal et autres
817 Background: Pegfilgastrim is administered 24 hrs after chemotherapy to reduce risks of myelosuppression. This requires an additional clinic visit, which can be difficult for some patients (pts) due to work and transportation issues. In GI malignancies, pts receiving capecitabine-based regimens also …
us
(code pays fourni par la source)
2020
conference-abstract
OpenAlex
Hasan Rehman, Jeffrey Chi, Nausheen Hakim, Shreya Goyal et autres
705 Background: Treatment with gemcitabine/nab-paclitaxel confers a survival benefit over gemcitabine monotherapy in APC. However, such treatment can be associated with significant toxicities especially in older patients and carries practical disadvantages related to a weekly schedule along with financial cost. We retrospectively …
us
(code pays fourni par la source)
Accès ouvert
2020
article
OpenAlex
Hasan Rehman, Jeffrey Chi, Nausheen Hakim, Shreya Goyal et autres
BACKGROUND: Treatment with gemcitabine/nab-paclitaxel confers a survival benefit over gemcitabine monotherapy in patients with advanced pancreatic cancer (APC). However, such treatment can be associated with significant toxicities especially in older patients and carries practical disadvantages related to a weekly schedule along with …
us
(code pays fourni par la source)
2013
article
OpenAlex
Karen Gleason, Eileen Brennan O'Neill, Jennifer Goldschmitt, J. L. Horigan et autres
Nurses in a hematology/oncology practice are responsible for the triage and management of phone calls from a diverse oncology population. An initiative was developed at the authors' institution to identify the educational needs of RNs while designing strategies to educate and improve …
us
(code pays fourni par la source)